Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.
about
Gene therapy in Parkinson's disease: rationale and current statusPromising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced deliveryCurrent approaches to enhance CNS delivery of drugs across the brain barriersRecombinant adeno-associated virus: efficient transduction of the rat VMH and clearance from blood.Convection-enhanced delivery of AAV2-PrPshRNA in prion-infected miceSafety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.AAV provides an alternative for gene therapy of the peripheral sensory nervous system.Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat.Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.Gene transfer to the CNS using recombinant adeno-associated virusGuided delivery of adeno-associated viral vectors into the primate brainControlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta.Dynamic contrast-enhanced MRI of Gd-albumin delivery to the rat hippocampus in vivo by convection-enhanced delivery.SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE.Real-time imaging of perivascular transport of nanoparticles during convection-enhanced delivery in the rat cortex.Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's diseaseConvection-enhanced delivery for the treatment of brain tumors.Recombinant adeno-associated virus type 2 pseudotypes: comparing safety, specificity, and transduction efficiency in the primate striatum. Laboratory investigation.Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.Novel drug delivery strategies in neuro-oncology.Adeno-associated virus vectors and neurological gene therapy.Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs.Anterograde axonal transport of AAV2-GDNF in rat basal gangliaLack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors.Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders.Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response.Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.Gene transfer to the rhesus monkey brain using SV40-derived vectors is durable and safe.
P2860
Q22241423-1636AD83-201B-4C67-9760-A65EC3BF7DBAQ26778701-E57C8D31-863F-46C5-A6F9-6E5799E65F3DQ26851517-71C25ABB-12DE-4F8B-967C-B7BCC0C89AD5Q30437835-B810E3F0-61D2-4585-BC68-2061E780986DQ33654870-1DC768BE-853D-4F29-A20C-7192538D3EE6Q33670676-72ADA0C5-460C-47F6-ADD0-BA28842E84CEQ33819946-F58AABBF-FB12-4956-B32D-13D1BE0EDFB0Q33822179-BAABEAD0-272D-4BA2-BF23-642C62DD3DEEQ33960090-9EAD1802-FF32-4544-B775-5DBD76268639Q34039452-62D8663B-90BC-490E-87A6-5D7D1AD7A406Q34055904-F3B277CF-E24F-4A56-A055-B22149410D17Q34061373-B5D80DF4-2D16-4FAC-A523-3D7FB0DDA382Q34158558-37525BC5-C2BA-4D83-AEE1-BBB35C38779DQ34318327-2C7A00B2-9FBB-4C09-BEF0-5988DE10A982Q34762396-58582807-BBC6-4E76-BD61-9A076859FAB1Q35785766-857E8D61-D587-44CF-8961-B8D778E509DEQ35932749-0E53F6BB-23C9-4B08-BA70-55444F7040FDQ36854365-BBB7F4E6-6E54-4C9B-BEFE-8FDEDE8BC5AFQ37171255-B8928963-B159-4527-B452-8E381C15EC00Q37301013-4EEF2DBB-C03B-4FF8-BFA5-98B36AEA6AC5Q37399627-CABB0EAF-0C11-4FF5-ADAA-1E7F9131C42FQ37533661-410E5309-C393-4BF1-B177-67B8E0A0953FQ38190041-240DCF07-6A79-4072-922B-2E065AEF7FEFQ38245677-42603C36-C76C-42D6-879A-FB0556470104Q39628466-FC3A04F0-CFFB-4E55-9575-DD9D23454BD3Q39737981-3314FB5F-DAC7-4535-99B5-F2137716FECBQ42428990-9D40DDEE-2838-4FEB-BE1C-8368FE9A3223Q42450986-761F24DB-6FC4-4A80-B094-3664A03888E8Q42502571-35A14F04-1D5F-4B90-A806-76EC16B6D30BQ45867822-D2EA4CB1-92DB-4265-AD08-C4C12464A5A1
P2860
Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biodistribution of adeno-assoc ...... on-enhanced delivery to brain.
@en
Biodistribution of adeno-assoc ...... on-enhanced delivery to brain.
@nl
type
label
Biodistribution of adeno-assoc ...... on-enhanced delivery to brain.
@en
Biodistribution of adeno-assoc ...... on-enhanced delivery to brain.
@nl
prefLabel
Biodistribution of adeno-assoc ...... on-enhanced delivery to brain.
@en
Biodistribution of adeno-assoc ...... on-enhanced delivery to brain.
@nl
P2860
P50
P356
P1433
P1476
Biodistribution of adeno-assoc ...... on-enhanced delivery to brain.
@en
P2860
P304
P356
10.1038/MT.2008.111
P4011
508c4f586067315376c6e7522a35b4d3640c193a
P407
P50
P577
2008-06-03T00:00:00Z